Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex, Inc. (NASDAQ: GNPX) has announced a registered direct offering of 4,000,000 shares of common stock at $6.25 per share to institutional investors. The offering, priced at-the-market under Nasdaq rules, is expected to close on or around February 11, 2021, pending customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for this deal. No warrants will be issued. The company aims to utilize the funds to advance its clinical-stage gene therapy programs, specifically targeting cancers and diabetes.
Genprex, a clinical-stage gene therapy company focused on cancer and diabetes, has established a Clinical Advisory Board (CAB) to support its oncology and diabetes programs. This board is composed of leading clinical specialists who will guide the development of Genprex’s REQORSA™ immunogene therapy for non-small cell lung cancer and its diabetes gene therapy. CEO Rodney Varner emphasized the importance of the CAB's expertise in advancing clinical trials. Notable members include Dr. Michael Morse from Duke University and Dr. George E. Peoples, a veteran in cancer vaccine development.
Genprex, Inc. (NASDAQ: GNPX) supports World Cancer Day to raise global cancer awareness and promote equity in healthcare. CEO Rodney Varner emphasized the company's dedication to innovative oncology treatments for patients with limited options. Genprex's lead candidate, REQORSA™, possesses FDA Fast Track Designation for non-small cell lung cancer (NSCLC) treatment in combination with AstraZeneca's Tagrisso®. Upcoming Acclaim-1 and Acclaim-2 trials are set to begin in the first half of 2021, focusing on NSCLC therapies.
Genprex, Inc. (NASDAQ: GNPX) announced a corporate update detailing its progress and plans for 2021. The company is set to initiate two pivotal clinical trials for its gene therapy candidate, REQORSA™, targeting non-small cell lung cancer (NSCLC). The Acclaim-1 trial will combine REQORSA with Tagrisso® for patients whose disease progressed after Tagrisso treatment, while Acclaim-2 will combine it with Keytruda® for low PD-L1 expressors. Genprex also highlighted $40 million in capital raised in 2020, strengthening its financial position.
Genprex, Inc. (GNPX), a clinical-stage gene therapy company, announced its participation in the Virtual Investor Conference Small and Microcap Showcase on February 4, 2021. CEO Rodney Varner will present an overview, highlighting recent advancements in clinical trials. The event starts at 11 a.m. EST, and the presentation will be available for replay on the company’s website after the conference. Genprex focuses on gene therapies for cancer and diabetes, with its lead product, REQORSA™, currently evaluated for treating non-small cell lung cancer (NSCLC).
Genprex (GNPX), a clinical-stage gene therapy company, will present at the MoneyShow Accredited Investors Virtual Expo from January 26-28, 2021. CEO Rodney Varner is scheduled to provide a company overview and discuss recent advancements in clinical trials on January 28 at 12:25 p.m. EST. The presentation will be available for replay on Genprex's website afterwards. Genprex focuses on innovative therapies for cancer and diabetes, with its lead product candidate, REQORSA™, being evaluated for non-small cell lung cancer and having received Fast Track Designation from the FDA.
Genprex, Inc. (NASDAQ: GNPX) announced its participation in NobleCon17, the annual investor conference, on January 19-20. CEO Rodney Varner will present a company overview, with a focus on advancements in clinical trials, at 3:45 p.m. EST on January 19. A video webcast will be available for replay on the company's website post-conference. Notably, Genprex was highlighted in a recent Channelchek report as the most read research report of 2020. The company focuses on innovative gene therapies, including its lead candidate REQORSA™ for non-small cell lung cancer.
Genprex, Inc. (GNPX) announced successful completion of its first scaled-up clinical-grade manufacturing run of REQORSA™ immunogene therapy, essential for upcoming Acclaim-1 and Acclaim-2 clinical trials targeting non-small cell lung cancer (NSCLC). All specifications have been met, enabling supply delivery to clinical trial sites pending FDA approval. The technology transfer to commercial CDMOs has been successfully completed. The trials aim to evaluate REQORSA in combination with AstraZeneca's Tagrisso® and Merck's Keytruda®, initiating in the first half of 2021.
Genprex (Nasdaq: GNPX) closed a registered direct offering of 3,116,884 shares of common stock at $3.85 per share, yielding gross proceeds of $12 million. The funds will support the Acclaim-1 and Acclaim-2 clinical trials for its gene therapy, REQORSA, in combination with AstraZeneca's Tagrisso and Merck's Keytruda, targeting non-small cell lung cancer. The offering was facilitated by A.G.P./Alliance Global Partners, and no warrants were issued. Net proceeds will be allocated to working capital and corporate purposes.
Genprex, Inc. (Nasdaq: GNPX) has entered into a securities purchase agreement with a healthcare-dedicated institutional investor to sell 3,116,884 shares of its common stock at $3.85 per share. This registered direct offering is priced at-the-market under Nasdaq rules, with no warrants issued. The closing is expected around December 24, 2020, subject to customary conditions. A.G.P./Alliance Global Partners acts as the sole placement agent. The offering is made under an effective shelf registration statement previously filed with the SEC.